JAN 09, 2018 06:42 AM PST

Protecting Against Glioblastoma

WRITTEN BY: Carmen Leitch
4 24 1390

Researchers at the Spanish National Cancer Research Centre (CNIO) have made progress in the fight against glioblastoma. They found that a protein, RanBP6, regulates a receptor that has a role in human development and cancer, epidermal growth factor receptor (EGFR). Reporting in Nature Communications, they found that by silencing RanBP6, glioma growth was promoted because EGFR expression was increased.  

Macroscopic pathology of Glioblastoma multiforme / Credit: Wikimedia Commons / Sbrandner

Of the roughly 100,00 new cases of malignant brain tumors that are diagnosed every year, glioblastoma is the deadliest and most common type of adult primary central nervous system tumor. The genome of glioma cells has been found to be incredibly complicated, however, and the effect of the many genetic mutations that arise is not known.

The Seve Ballesteros Foundation-CNIO Brain Tumor Group, headed by Massimo Squatrito, in collaboration with the laboratory of Ingo Mellinghoff at the Memorial Sloan-Kettering Cancer Center in New York, has now uncovered a novel mechanism that contributes to preventing glioblastoma development.

EGFR has a critical role in normal development, as well as in human cancer, making it a major drug target in cancer therapeutics. Dysfunctional activation of EGFR can cause tumors to grow. It has been suggested that increases in gene copy numbers and gain-of-function mutations are to blame, but problems in the regulation of EGFR can also be a cause.

Study co-lead authors Barbara Oldrini and Wan-Ying Hsieh found a new player in EGFR regulation. An uncharacterized protein, RanBP6, was identified as a modulator of EGFR expression. RanBP6 is a member of the importin family that regulates the import of signal transducer and activator of transcription 3 (STAT3) to the nucleus. When RanBP6 is halted, STAT3 nuclear translocation is impaired; then there is less transcription of EGFR, increasing EGFR pathway output.

"Our studies showed for the first time that STAT3 is a direct inhibitor of EGFR expression. I believe this has important clinical implications: STAT3 inhibitors are currently being investigated for the treatment of glioblastoma and other tumor types. Inhibiting STAT3 signaling could lead to an undesired activation of EGFR signaling,” explained Massimo Squatrito.

Some deletions of RanBP6 were found in some glioblastoma patients. Silencing RanBP6 caused growth glioma in a mouse glioma model, due to an upregulation of EGFR.

"Our results provide an example of EGFR deregulation in cancer through silencing of components of the nuclear import pathway. We have identified a new link between the Ran-GTPase nuclear transport pathway and key cancer signaling pathways which warrant further study as inhibitors targeting nuclear transporters enter clinical evaluation as cancer therapeutics,” concluded Barbara Oldrini.

This group has been working to treat brain tumors for years; learn more about their lab from the video.

Sources: AAAS/Eurekalert! Via CNIO, Nature Communications

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 30, 2018
JUN 30, 2018
CD4 T Cells Responsible for Inflammatory Bowel Disease
A specific subset of immune cells could be targeted to better treat inflammatory bowel disease (IBD). A new University of Alabama at Birmingham study point
JUL 07, 2018
JUL 07, 2018
A New Target for an Effective Gonorrhea Treatment
Many pathogens are becoming antibiotic resistant; the microbe that causes the STD gonorrhea is no different.
JUL 12, 2018
JUL 12, 2018
Understanding Vascular Dementia
Dementia is a growing problem for healthcare providers, patients, and families. It’s estimated that 47 million people are living with dementia worldw
JUL 17, 2018
Genetics & Genomics
JUL 17, 2018
CRISPR can Seriously Damage the Genome
The CRISPR/Cas9 gene-editing system took the research world by storm when it was first introduced. Now there are concerns.
AUG 01, 2018
Cell & Molecular Biology
AUG 01, 2018
Levels of One Molecule, LAC, can Diagnose Depression
Depression can be hard to classify and therefore, challenging to treat. New work could help change that.
AUG 04, 2018
Cell & Molecular Biology
AUG 04, 2018
Bioengineered Lung Successfully Grown and Transplanted
The complexity of human organs has made them difficult to engineer, but real progress is being made.
Loading Comments...